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https://doi.org/10.1016/j.celrep.2020.107674SUMMARYAlthough an increasing number of beneficial microbiome members are characterized for the human gut and
vagina, beneficial microbes are underexplored for the human upper respiratory tract (URT). In this study, we
demonstrate that taxa from the beneficial Lactobacillus genus complex aremore prevalent in the healthy URT
than in patients with chronic rhinosinusitis (CRS). Several URT-specific isolates are cultured, characterized,
and further explored for their genetic and functional properties related to adaptation to the URT. Catalase
genes are found in the identified lactobacilli, which is a unique feature within this mostly facultative anaerobic
genus. Moreover, one of our isolated strains, Lactobacillus casei AMBR2, contains fimbriae that enable
strong adherence to URT epithelium, inhibit the growth and virulence of several URT pathogens, and suc-
cessfully colonize nasal epithelium of healthy volunteers. This study thus demonstrates that specific lactoba-
cilli are adapted to the URT and could have a beneficial keystone function in this habitat.INTRODUCTION
The upper respiratory tract (URT) is a crucial barrier with the
external airborne environment. It is home to an important part
of the commensal microbiota, which is essential for URT homeo-
stasis and its optimal functioning (reviewed in Man et al., 2017).
Although the development of next-generation sequencing tech-
niques has revealed which bacteria are present in the different
URT niches (De Boeck et al., 2017; Ramakrishnan et al., 2013;
Stearns et al., 2015), most studies are observational without
functional exploration of the role of specific bacterial members
in URT health and disease. A new understanding of the beneficial
functions of these commensals is required for the design of tar-
geted approaches to modulate the bacteria in the URT and to
prevent or treat symptoms. For example, chronic rhinosinusitis
(CRS) affects more than 11% of the European population and
causes a major burden on public health (Fokkens et al., 2020).
The disease is often treated with antibiotics, but their effective-
ness is questionable because the involvement of specific patho-
genic bacteria as disease modulators of CRS is still controversial
(Hellings et al., 2017). Moreover, if the disease and/or its persis-This is an open access article under the CC BY-Ntence is rather the result of polymicrobial microbiome distur-
bances than single pathogens, alternative strategies such as mi-
crobiome modulation should be evaluated. One approach could
consist of the addition of probiotics, i.e., live micro-organisms
that, when administered in adequate amounts, confer a health
benefit on the host (Hill et al., 2014). Although probiotics have
been widely explored in gastrointestinal applications, studies
on their importance, habitat adaptation, and use for topical appli-
cations outside the gut, for instance in the URT, are still very
limited.
Here, we investigated whether lactobacilli, which are impor-
tant taxa in several habitats of the human body, could also be
important for the URT. We started by sequencing and phyloge-
netic placement of the amplicon sequence variants (ASVs) of
the 16S rRNA V4 gene region of URT samples taken from 100
healthy volunteers and 225 patients with CRS. We then aimed
to cultivate lactobacilli from different healthy URT samples and
implemented a combination of genomic and functional in vitro
and in vivo analyses to explore their habitat adaptation to the hu-
man URT and their potential as URT probiotic. The colonization
capacity of one nasopharynx-isolated strain of the lactic acidCell Reports 31, 107674, May 26, 2020 ª 2020 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Prevalence and Abundance of
Lactobacilli in the URT of Healthy Controls
and CRS Patients
(A) Compositional differential abundance of the 30
most prevalent families between the healthy con-
trol and CRS samples in the anterior nares. Each
tile shows an estimate of the differential abun-
dance of a bacterial family on the y axis, relative to
a family on the x axis. A plus/minus signmeans that
the family is significantly more/less abundant in
healthy controls compared with CRS patients, with
a false discovery rate of 10%. See also Figure S1
for the nasopharynx.
(B) Prevalence of taxa from the Lactobacillus
genus complex (LGC) in the anterior nares (left) and
in the nasopharynx (right) from healthy controls
and CRS patients. Asterisks represent statistically
significant differences between the niches (***p <
0.001, ****p < 0.0001).
(C) Relative abundance of taxa from the LGC upon
presence in the anterior nares (left) and naso-
pharynx samples (right) from healthy controls and
CRS patients. p values (Wilcoxon rank-sum tests)
are indicated on the plot. Pseudocounts of 1 were
added to all samples to allow visualization on the
log scale. Samples where the LGCwas found to be
present are represented by dark blue points,
whereas samples where the LGC was absent are
colored light blue.
(D) Top 11 of themost abundant bacterial genera in
nasopharynx samples of healthy controls and CRS
patients. The LGC is part of the residual, ranked at
number 21.
(E) Zoom in on the LGC phylogroups (Duar et al.,
2017) in nasopharynx samples of healthy controls
and CRS patients.
(F) Lactobacillus species isolated via selective
cultivation and identified up to species level
after whole-genome sequencing and comparative
genomics.
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OPEN ACCESSbacteria (LAB), genetically and functionally shown to be adapted
to several biotic and abiotic factors of this underexplored human
body site, was then evaluated in healthy volunteers.
RESULTS
Lactobacillus Genus Complex Is Reduced in the URT
Microbiome of CRS Patients
The Lactobacillus genus complex (LGC) includes important
beneficial taxa in different human body niches (Heeney et al.,
2018; Lebeer et al., 2018; Petrova et al., 2015). The bacteria
belonging to this genus are known to be rod shaped, fermenta-
tive bacteria producing lactic acid from sugar fermentation under2 Cell Reports 31, 107674, May 26, 2020anaerobic or micro-aerophilic conditions.
This lactic acid production is a hallmark of
their beneficial functions, because it in-
hibits the growth of pathogens. In addi-
tion, also their long history of safe use
and their beneficial immunomodulatory,
metabolic, and epithelial cell interactionsoften underlie the beneficial roles of lactobacilli (Lebeer et al.,
2008). To investigate whether the LGC could also be associated
with URT health, we first compared the abundance of bacterial
taxa at the family level between CRS patients versus healthy
controls using a compositional data analysis approach. In brief,
we calculated the pairwise relative abundance log ratios be-
tween all families and compared these between the two groups
of samples. We did this for the 30most prevalent families, result-
ing in 30 comparisons per family. Compared with CRS patients,
two families were significantly more abundant in the anterior
nares of healthy controls with respect to a large number of refer-
ence families (Figure 1A):Carnobacteriaceae and the LGC or lac-
tobacilli. Similar results were obtained for the nasopharynx
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OPEN ACCESS(Figure S1). The LGC was almost 1.5-fold enriched in the healthy
controls based on their prevalence, both in the anterior nares and
the nasopharynx (Figure 1B). In the anterior nares, taxa from the
LGC were found in 87% of the healthy control samples, as
opposed to 60% in CRS (Fisher’s exact test, p = 0.000007). A
similar trend was observed in the nasopharynx, with 80% in
the healthy controls versus 55% in CRS patients (Fischer’s exact
test, p = 0.00006). Also, the median relative abundance of ASVs
from the LGC was more than 3-fold higher in the anterior nares
(Wilcoxon rank-sum test, p < 10e7) of healthy controls
compared with those of CRS patients and more than 10-fold
higher in the nasopharynx (Wilcoxon rank-sum test; p < 10e7)
(Figure 1C). Although the URT is dominated by other bacterial
genera (Figure 1D), the LGC thus represents a minor, yet non-
negligible genus in the URT, which is clearly enriched in healthy
volunteers based on prevalence, relative abundance, and
compositional analyses.
Themost abundant LGC ASVs in the nasopharyngeal samples
over the entire dataset were classified within the Lactobacillus
casei group (new genus name Lacticaseibacillus) (Zheng et al.,
2020) according to the EZBioCloud 16S rRNA database (Yoon
et al., 2017) and mean relative abundance of 0.16%, the Lacto-
bacillus delbrueckii group (Lactobacillus genus strictu sensu ac-
cording to Zheng et al., 2020) (Lactobacillus iners, 0.12%), the
Lactobacillus plantarum group (new genus name Lactiplantiba-
cillus) (0.12%), and the Lactobacillus sakei group (new genus
name Lactilactobacillus sakei) (0.09%) (Figure 1E). For clarifica-
tion, this manuscript still uses the old taxonomy names, because
the reclassification was publicly available only after acceptance
of this manuscript. However, a list of the new Lactobacillus spe-
cies names according to the reclassification by Zheng et al.
(2020) can be found in Data S1. Especially the detection of a
L. iners ASV (in 21% of the samples) was surprising, because
this species has been mainly associated with the human vagina
(Gajer et al., 2012; Petrova et al., 2017), althoughwe recently also
found it on the human facial skin (Lebeer et al., 2018; Ross et al.,
2017). Of interest, the same ASVs of lactobacilli were also most
abundant, be it at lower relative abundances (<0.1%), in the
anterior nares, which is a more oxygen-rich habitat and thus
less favorable for fermentation.
Subsequently, we aimed to cultivate these LGC species from
URT samples from our healthy subjects. The isolation of lactoba-
cilli from URT samples turned out to be challenging, because of
the high abundance of fast-growing aerobes such as staphylo-
cocci, even on selective culture media and conditions for lacto-
bacilli (Kandler and Weiss, 1986). Additionally, it is possible that
the targeted lactobacilli have undergone unidentified adapta-
tions to the URT habitat, making it more challenging to grow
them under standard growth conditions. From the 100 healthy
volunteers sampled, nine isolates were obtained, whole-genome
sequenced. and classified at species level as L. rhamnosus,
L. casei, L. sakei, and L. plantarum. Of note, these taxa were
also found to be among the most abundant Lactobacillus ASVs
based on the microbiome profiles (Figure 1E). Six
L. rhamnosus strains were isolated (L. rhamnosus strains
AMBR1, AMBR3, AMBR4, AMBR5, AMBR6, and AMBR7), one
L. casei (strain AMBR2), one L. sakei (strain AMBR8), and one
L. plantarum (strain AMBR9) (Figure 1F). To study the geneticrelatedness of the isolated strains and track the possible sources
of these lactobacilli, we constructed a phylogenetic tree of the
genomic assemblies together with the publicly available genome
sequences from Sun et al. (2015) (Figure S2). In addition, pair-
wise average nucleotide identity (ANI) values were calculated
for all genomes under study. High pairwise ANI values were ob-
tained for L. rhamnosus AMBR1, AMBR5, AMBR6, and AMBR7
with the model gastrointestinal probiotic L. rhamnosus
GG (GCA_003353455, GCA_000026505, GCA_000011045;
99.82%–99.99%), for L. rhamnosus AMBR3 and AMBR4 with
type strain L. rhamnosus DSM20021 (GCA_001435405;
99.72%–99.99%), and for L. plantarum AMBR9 with
L. plantarum CMPG5300 (GCA_000762955; 99.96%–99.98%)
(Malik et al., 2014). Furthermore, variant calling of these genome
sequences resulted in a low number of single-nucleotide poly-
morphisms. These isolates thus appeared to be highly similar
or even identical to commercially available probiotics that prob-
ably originate from oral consumption, because the oral cavity
and nasopharynx are connected. However, L. casei AMBR2
(maximum [max.] ANI value of 96.97%) and L. sakei AMBR8
(max. ANI value of 98.41%) showed max. ANI values lower
than 99%, indicating that these isolates are more distinct from
the publicly available genome sequences of mainly food-related
lactobacilli and might be more adapted to the URT.
Adaptation of URT Lactobacilli to Oxidative Stress and
Nasal Epithelial Adherence
To examine the adaptation capacity to typical conditions of the
URT, such as high air flow and oxidative stress (De Rudder
et al., 2018), the AMBR genomes were first screened for the
presence of genes encoding catalases, superoxide dismutase,
and related enzymes, known to be important for oxidative stress
tolerance of bacteria in the respiratory tract (Eason and Fan,
2014). Catalase enzymes are uncommon in lactic acid-ferment-
ing bacteria (Weinberg, 1997). Here, we found a gene encoding a
heme- and a manganese-dependent catalase in isolate L. casei
AMBR2 (as reported in Wuyts et al., 2017), and a heme-depen-
dent catalase gene in L. sakei AMBR8 and L. plantarum
AMBR9. Experimental validation showed that L. casei AMBR2
and L. plantarum AMBR9 indeed exhibit catalase activity under
respiratory conditions, although this was not observed for
L. sakei AMBR8 (Table S1). Further screening of the AMBR8
genome revealed the presence of inverted repeats in the leader
sequence of the catalase gene, implying possible phase varia-
tion (van der Woude and Ba¨umler, 2004) (Figure S3). L. casei
AMBR2 showed catalase activity both under aerobic and respi-
ratory conditions (Table S1). Further screening of the evolu-
tionary history of these enzymes in the whole LGC revealed
that the heme-dependent catalase was found in all LGC taxa
associated above with the URT in our 16S analysis, albeit with
varying copy numbers (Figure 2, left). The phylogenomic analysis
also indicated that a heme-dependent catalase was already pre-
sent in their common ancestor, and thus encoded by a core gene
in these phylogenetic groups. The manganese-dependent cata-
lase appeared to be less conserved and was found as a core
gene only in L. casei, Lactobacillus kunkeei (new genus name
Apilactobacillus kunkeei), and Lactobacillus lindneri (new genus
name Fructilactobacillus lindneri) (Figure 2, right). The two latterCell Reports 31, 107674, May 26, 2020 3
Figure 2. Adaptation of URT Lactobacilli to Oxidative Stress
(Left) Phylogenomic screening for heme-dependent catalase in the evolutionary history of the LGC based on a profile Hidden Markov Model (HMM) database
constructed for the catalase gene families.
(Right) Phylogenomic screening for manganese-dependent catalase in the evolutionary history of the LGC. Given a species with n genomes, a gene was
considered core for that species if it was found in n-1 or n genomes and accessory if it was found in 1 to n-2 genomes.
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not directly related to the human URT, but where also consider-
able oxidative stress could be envisaged (Anderson et al., 2018;
Oliveira et al., 2011).
Because the capacity to tolerate oxidative stress has been
linked to the growth capacity of LAB (Zotta et al., 2017), and
because this is a key property for later development as a probi-
otic, we also explored the growth capacity, production rate, and
cell dry weight of the AMBR isolates via batch fermentations
(500 mL) in de Man, Rogosa, and Sharpe (MRS) medium at
37C. The most oxidative stress-tolerant L. casei AMBR2 turned
out to be one of the most robust strains in comparison with the
other AMBR strains and the model strain L. rhamnosus GG.
AMBR2 showed a desired growth capacity of more than 2 3
109 colony-forming units (CFU)/mL after 48 h (Figure S4A), a pro-
duction rate of more than 75% (Figure S4B), and a cell dry weight
of more than 1.5 g/L medium (Figure S4C).4 Cell Reports 31, 107674, May 26, 2020Another adaptation to the URT is a sufficient high adherence
capacity to nasal epithelium to prevent rapid nasal clearance.
Therefore, we screened the genomes of our isolates for genes
related to adhesive capacities. A SecA2/SecY2 secretion system
with two large glycosylated putative surface adhesion proteins
(srr1 and srr2 gene) was found in the draft genome sequence
of L. casei AMBR2 (Wuyts et al., 2017) (see also Figure S5 for a
schematic model for srr glycoprotein biogenesis) (Couvigny
et al., 2017). Based on the gene sequences, the molecular
weights of the two serine-rich repeat proteins were estimated
at 290 and 738 kDa, which was confirmed via SDS-PAGE (Fig-
ure S6). In the closely related L. casei DSM20178, both srr genes
and the secretion system were also identified. Therefore, we hy-
pothesize that this strain might have similar adhesive structures
on its cell surface as L. casei AMBR2 (Wuyts et al., 2017). In addi-
tion, the type strain L. casei ATCC393 and L. casei JCM1134
have the srr2 gene, but no SecA2/SecY2 secretion system,
Figure 3. Adherence Properties to Overcome
Nasal Clearance
(A) Scanning electron microscopy (SEM) of the URT
isolate L. casei AMBR2 cell surface shows long,
spike-like fimbriae. See also Figure S7 for SEM of
closely related L. casei strains.
(B) For comparison, visualization of the SpaCBA pili
on the cell surface of L. rhamnosus GG using SEM.
(C) SEM of the URT isolate L. sakei AMBR8 cell
surface indicating no fimbriae structures present on
the bacterial cell surface under the tested condi-
tions. Scale bars, 1 mm.
(D) Overnight-grown cultures of L. rhamnosus
AMBR1, L. casei AMBR2, L. rhamnosus AMBR4,
L. sakei AMBR8, and the model strain L. rhamnosus
GG were co-incubated with Calu-3 cells for 1 h in a
final concentration of 108 CFUs/mL. In addition,
three closely related L. casei strains, i.e., L. casei
DSM20178, L. casei ACC393, and L. casei
JCM1134, were analyzed as well to compare
adherence of these strains with L. casei AMBR2.
The proportion of adhered bacteria, expressed as a
percentage, was determined. Significant differ-
ences compared with L. casei AMBR2 are indicated
with an asterisk (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001). Data of three biological repetitions
are represented as mean ± standard deviation (SD).
(E) Overview of predicted or confirmed fimbriae
structures based on the spaCBA, srr2, and secA2/
secY2 gene cluster in the tested strains based on
their genome sequence and SEM.
(F and G) Overnight-grown L. casei AMBR2, L. sakei
AMBR8, and L. rhamnosus GG were co-incubated
with primary NECs of healthy control donors (n = 6)
(F) or CRSwNP patients (n = 6) (G) for 1 h in a final
concentration of 108 CFUs/mL. The proportion of
adhered bacteria, expressed as a percentage, was
determined.
Significant differences are indicated with an asterisk
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Data are represented as mean ± SD. One-way ANOVA and multiple t tests were used to determine statistical significance in GraphPad Prism. The p value was
corrected for multiple comparisons using the Holm-Sidak’s multiple comparisons test (D, F, and G). See also Table S2.
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fimbriae structures. These findings were confirmed by scanning
electron microscopy (SEM) analysis. SEM showed the presence
of long, spike-like appendages on the cell surface of L. casei
AMBR2, which stretched out with lengths ranging up to 2 mm
long. They are referred to as fimbriae based on this initial visual-
ization of their morphology (Figure 3A). Also, L. casei DSM20178
showed fimbriae structures on SEM images, although they
were less prominent compared with L. casei AMBR2 (Fig-
ure S7A). L. casei ATCC393 and L. casei JCM1134 did not
show fimbriae structures on SEM (Figures S7B and S7C). The
fimbriae observed in L. casei AMBR2 clearly differed from the
well-described SpaCBA pili of model intestinal probiotic
L. rhamnosus GG, which are more limp and shorter in length
ranging between 0.1 and 1 mm (Figure 3B; Table S2). Phyloge-
nomic analysis of the srr genes that potentially express this
phenotype in L. casei AMBR2 suggested these srr genes to be
unique for these L. casei strains, because it was not found in
the other isolated LGC AMBR strains isolated here or other spe-
cies of lactobacilli analyzed earlier (Wuyts et al., 2017). Incontrast, all L. rhamnosus AMBR strains had the spaCBA gene
cluster present in their genomes, encoding the SpaCBA pili, as
described for L. rhamnosus GG (Kankainen et al., 2009). Also,
L. sakei AMBR8 showed the spaCBA gene cluster in its genome,
but SEM revealed that L. sakei AMBR8 did not express fimbriae
on its cell surface under the tested conditions (Figure 3C). Explo-
ration of this gene cluster revealed the presence of inverted re-
peats in the leader sequence of the spaCBA cluster, possibly re-
sulting in abolished expression, as also observed for the catalase
gene (Figure S3). Finally, we experimentally validated the adhe-
sion capacity of L. rhamnosus AMBR1, L. casei AMBR2,
L. rhamnosus AMBR4, L. sakeiAMBR8, thewell-known probiotic
L. rhamnosus GG, and the three closely related L. casei,
DSM20178, ATCC393, and JCM1134, to the respiratory tract
epithelial Calu-3 cell line and human primary nasal epithelial cells
(NECs). The latter cell type was used for confirmation, because it
has previously been shown to better represent the nasal epithe-
lial cellular responses, morphology, biochemical characteristics,
and donor variation than immortalized cell lines (Martens et al.,
2018). Primary cells from both healthy control donors (n = 6)Cell Reports 31, 107674, May 26, 2020 5
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included, because we rationalized that adhesion to diseased or
unstable epithelium could be different due to, for instance, the
expression of different receptors (Boita et al., 2016). In Calu-3
cells, adhesion of L. casei AMBR2 was significantly higher
(11.3% ± 3.2%) compared with L. rhamnosus GG (5.7% ±
2.7%; p < 0.0001), L. rhamnosus AMBR1 (2.6% ± 1%; p <
0.0001), and L. rhamnosus AMBR4 (6% ± 1.4%; p < 0.001) (Fig-
ure 3D). In comparison with the other tested L. casei strains,
adherence of L. casei AMBR2 was similar to that of L. casei
DSM20178 (12.6% ± 3.4%), in accordance with our findings
based on their genomes and SEM that both strains express
fimbriae-like Srr2/SecA2/SecY2-dependent structures (Fig-
ure 3E). Adherence of L. casei ATCC393 (5.7% ± 3%) and
L. casei JCM1134 (7.5% ± 1.6%) was significantly lower
compared with L. casei AMBR2, in agreement with their
genome-lacking genes encoding SecA2/SecY2. Because
L. casei AMBR2 and L. sakei AMBR8 showed the best adhesion
capacity to the Calu-3 cells of our URT isolates, these strains
were further investigated in the primary NECs. L. casei AMBR2
exhibited a superior capacity (p = 0.0002) to adhere to NECs
from controls compared with L. sakei AMBR8, with adhesion
percentages of 15.8% and 8.3%, respectively (Figure 3F).
Finally, adherence of the three tested strains was not influenced
by disease status, because adherence was similar in primary
cells from healthy controls and patient-derived cells (CRSwNP)
(Figure 3G).
L. casei AMBR2 Has Antimicrobial and
Immunomodulatory Properties against Important URT
Pathobionts
Next, we performed a more in-depth analysis of L. casei AMBR2
and L. sakei AMBR8 to better evaluate their adaptability in terms
of ecological interactions with dominant competing URT patho-
gens and tolerability by the nasal epithelium. KeyURT pathogens
are Staphylococcus aureus, Haemophilus influenzae, and Mor-
axella catarrhalis, which are all able to take a dominant niche
as pathobionts in the URT upon infection. The capacity to pre-
vent overgrowth of these pathogens can thus be considered
as a keystone beneficial function. S. aureus and H. influenzae
are often indicated as CRS pathobionts (Bachert et al., 2010;
De Boeck et al., 2019; Hoggard et al., 2017).M. catarrhalis tends
to be a marker for acute sinusitis (Brook et al., 2006; Murphy and
Parameswaran, 2009), although it is also detected in the sinuses
of CRS patients (De Boeck et al., 2019; Chalermwatanachai
et al., 2018; Hoggard et al., 2017). Analysis of direct, antimicro-
bial effects of L. casei AMBR2 against these URT pathobionts
via spot assays revealed growth inhibition for all three (Figure 4A),
with the largest activity against M. catarrhalis. In contrast, the
pathobionts showed no growth inhibition against themselves.
Subsequently, we showed that respiratory epithelial cells did
tolerate L. casei AMBR2 and L. sakei AMBR8 well, because
they responded much less with production of interleukin-8
(IL-8), IL-1b, and tumor necrosis factor (TNF) to both lactobacilli
in comparison with the tested pathogens, similarly to model pro-
biotic L. rhamnosus GG (Figure 4B). IL-1b, TNF, and IL-8 are
known to have important pro-inflammatory action in CRS (Cervin
and Wallwork, 2007; Tomassen et al., 2016), and IL-8 and IL-1b6 Cell Reports 31, 107674, May 26, 2020are in addition important for neutrophil recruitment (Suzuki and
Ikeda, 2002). No signs of virulence by invasion or destruction
of the cells were observed for the tested lactobacilli. No increase
in the inflammatory response was observed for any of the inves-
tigated pathogens upon co-culture with our selected Lactoba-
cillus strains (Figures 4C–4E; see Table S3 for statistical anal-
ysis). We rather observed anti-inflammatory effects: L. casei
AMBR2, but not L. sakei AMBR8, was able to significantly
decrease the IL-8 (p = 0.02) and IL-1b (p = 0.01) expression
induced by M. catarrhalis (Figure 4C). For H. influenzae, a
decreasing tendency in the inflammatory response was also
observed in co-culture with L. casei AMBR2 (Figure 4D). The
anti-inflammatory action of L. casei AMBR2 was the least pro-
nounced against S. aureus (Figure 4E), probably because the
inflammation induced by this pathogen is significantly higher
compared with M. catarrhalis and H. influenzae. Co-culture of
L. sakei AMBR8 with H. influenzae showed an increasing ten-
dency of TNF induction. Although this was not statistically signif-
icant, AMBR2 was preferred over AMBR8 for further analyses.L. casei AMBR2 Temporarily Colonizes the Nasal Cavity
of Healthy Volunteers without Adverse Effects
Finally, we aimed to validate our in vitro and ex vivo findings
in vivo. Animal models are often an important intermediate step
between in vitro characterization and human trials. However,
most animal models have a different URT anatomy and physi-
ology compared with humans, making the translation highly
challenging. Therefore, because lactobacilli have a long history
of safe and frequent use, especially for strains from the
L. casei group (Sanders et al., 2010), and a qualified presumption
of safety state (QPS) in Europe (Koutsoumanis et al., 2019), we
aimed to validate our findings in humans, after some additional
analyses. First, considering that the presence of transferable
antibiotic resistance markers is an undesired characteristic for
anymicrobe introduced in humans as potential probiotic or other
microbiome therapeutic (EFSA Panel on Additives and Products
or Substances used in Animal Feed, 2012), we performed a thor-
ough in silico-based analysis of the genomes, confirming that
chromosomal and plasmid antibiotic resistance genes were
not present, except for a tetracycline resistance gene in
L. rhamnosus AMBR1, AMBR5, and AMBR6 (Figure 5). Minimal
inhibitory concentration (MIC) testing in vitro according to the Eu-
ropean Food Safety Authority (EFSA) guidelines (EFSA Panel on
Additives and Products or Substances used in Animal Feed,
2012) showed that all AMBR strains were susceptible to tetracy-
cline (Figure 5). Some strains did show limited in vitro resistance
against certain antibiotics (Figure 5), although known antibiotic
resistance genes were not found in the genomes of these iso-
lates. Intrinsic phenotypic antibiotic resistance is generally not
considered a safety issue, because it cannot be horizontally
transferred, but it should be kept to a minimum (EFSA Panel on
Additives and Products or Substances used in Animal Feed,
2012). L. caseiAMBR2was the only isolated strain that displayed
no antibiotic resistance based on in silico and in vitro phenotypic
analysis (Figure 5), and thus was the most appropriate candidate
for human testing. Furthermore, genomic screening against the
Virulence Factor Database (VFDB) (Liu et al., 2019) also did not
Figure 4. Antimicrobial and Immunomodulatory Functions for URT Lactobacilli
(A) Agar-based antimicrobial screening of the interaction between live lactobacilli and S. aureus,M. catarrhalis, andH. influenzae. Data are expressed asmeans ±
SDs.
(B) Lack of induction of an inflammatory response in respiratory epithelial cells. Induction of IL-8, IL-1b, and TNF mRNA by L. rhamnosus GG, L. casei AMBR2,
L. sakei AMBR8, S. aureus,M. catarrhalis, and H. influenzae in Calu-3 cells. Bacteria were incubated with the cells for 4 h in a final concentration of 108 CFUs/mL.
MEM refers to the condition of cells alone without any bacteria. The presented data are representative of three independent experiments, with each experiment
three biological repetitions. Significant differences between all tested conditions were evaluated with one-way ANOVA and multiple t tests in GraphPad Prism.
The p value was corrected for multiple comparisons using the Holm-Sidak’s multiple comparisons test. Significant differences of the immunomodulation of the
pathobionts with L. casei AMBR2 are depicted with asterisks (*) and for L. sakei AMBR8 with degree signs (). More details about the significance and other
statistical results can be found in Table S3. Data are expressed as mean ± range (B) and means ± SDs (C–E).
(C) Beneficial homeostatic immunomodulatory function of URT lactobacilli. Induction of IL-8, IL-1b, and TNF mRNA by M. catarrhalis upon co-incubation with
lactobacilli in Calu-3 cells.
(D) Induction of IL-8, IL-1b, and TNF mRNA by H. influenzae upon co-incubation with lactobacilli in Calu-3 cells.
(E) Induction of IL-8, IL-1b, and TNF mRNA by S. aureus upon co-incubation with lactobacilli in Calu-3 cells.
One-way ANOVA and multiple t tests were used to determine statistical significance in GraphPad Prism. The p value was corrected for multiple comparisons
using the Holm-Sidak’s multiple comparisons test (C–E). Results represent three biological repetitions (C–E).
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toxins.
Based on the safety assessment resulting from our detailed in
silico and in vitro analysis, and given earlier described literature
on the safe administration of related bacteria (LGC taxa and
Streptococcus salivarius) in the nose of healthy and even
diseased adult individuals (Ma˚rtensson et al., 2016, 2017; Santa-
gati et al., 2015), we received approval from the ethical commit-
tee (B300201835709) to explore the in-human adaptation and ef-fects of L. casei AMBR2. Therefore, we set up an open-label
exploratory study in 20 healthy volunteers, who administered
spray-dried L. casei AMBR2 powder in the nose twice daily for
2 weeks. In brief, bacteria were spray dried and nasal-spray for-
mulations were prepared, as described in the Method Details
section. Participants resolved the powder daily in physiological
water prior to use and administered at least 108 CFUs/puff in
the nostril. Tables S4 and S5 give an overview of participant de-
mographics and probiotic consumption of the participants,Cell Reports 31, 107674, May 26, 2020 7
Figure 5. Antibiotic Resistance In Silico and In Vitro for All Isolated
AMBR Strains
G, genome analysis; L, in vitro testing via MIC assay; dark blue, no hit/sus-
ceptible to antibiotic; light blue, hit/not sensitive to antibiotic.
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OPEN ACCESSrespectively. The primary outcome measure of this study was to
evaluate the fitness of L. casei AMBR2 in the healthy naso-
pharynx and its detection by DNA- and culture-based analysis
after nasal administration. We determined that temporary URT
colonization of sufficient numbers of L. casei AMBR2, preferably
above 15min, is an important milestone toward the development
of a novel nasal probiotic to prevent immediate nasal clearance.
Additionally, this in vivo persistence also gave us an idea about
the ecological relevance and adaptation potential of lactobacilli
in the human nose. In parallel, the modulation of the URT micro-
biome was followed during the study period. The second
outcome measure was to evaluate the safety and tolerability of
two doses of 108 CFUs/day of nasal L. casei AMBR2.
The persistence capacity of L. casei AMBR2 in the URT was
investigated based on selective cultivation, 16S rRNA V4
sequencing, and qPCR analyses with strain-specific primers,
targeting the srr2 gene (putative fimbriae) for L. casei AMBR2
of nasopharyngeal swabs. These were sampled at four time
points (Figure 6A; Table S6). L. casei AMBR2 could be cultivated8 Cell Reports 31, 107674, May 26, 2020from all samples at T1 (5 min after first administration), in 73% of
the samples at T2 (within 10–16 h after the last administration at
the end of the 14-day treatment), and in none of the samples at
T3 (2 weeks after the last administration). qPCR targeting of the
srr2 gene of L. casei AMBR2 (Figure 6B) yielded a similar trend in
colonization potential. Based on a standard curve, the amount of
L. casei AMBR2 was estimated to vary between 43 106 and 43
108 CFUs per nasopharyngeal swab at T1. At the second consul-
tation (T2), the amount had decreased and varied between 1.53
103 and 53 107 CFUs. At T3, the strain could still be detected in
two participants (z103 CFUs). A similar trend was observed in
the sequencing profiles. Of interest, the participants of this study
did not contain the specific L. casei AMBR2 strain in their nose at
T0 (start of the study), but other strains were present, including
L. casei/paracasei/zeae, L. iners, and L. curvatus/sakei. A signif-
icant increase in the relative abundance of the LGC indicating
different species based on their V4 sequence was observed at
T1 (p < 0.0001), which was associated with a temporary
decrease in the relative abundance of the other genera, some
of which harbored some potential URT pathobionts such as
C. tuberculostearicum, H. influenzae/aegyptius, and S. aureus
(Figure 6C). At T2, the relative abundance of the LGC was
decreased compared with the previous time point, although
high relative abundances were still detected in several samples.
For other genera, such as Corynebacterium, Staphylococcus,
and Streptococcus, an initial drop in relative abundances was
observed at T1, but their abundances started to increase again
at T2, indicating no apparent side effects on the supposedly
healthy URT microbiome profiles (Figure 6C). Of interest, the ef-
fects of L. casei AMBR2 on the relative abundance of the genus
Dolosigranulum seemed to be long-lasting compared with the
other genera. Dolosigranulum, a member of the Carnobacteria-
ceae and the LAB, has been linked to healthy respiratory condi-
tions based on several microbiome studies (Biesbroek et al.,
2014; De Boeck et al., 2019; Laufer et al., 2011). It is thus plau-
sible that lactobacilli and Dolosigranulum have mutually exclu-
sive beneficial functions as LAB in the nose and nasopharynx,
but this remains to be explored in future work.
In addition to the temporary colonization capacity, the safety
and tolerability of L. casei AMBR2 upon nasal administration
were evaluated via reported symptoms, physical examination
of the URT by the responsible ENT (ears, nose, and throat)
specialist, and measurement of markers in the blood of the par-
ticipants. First, the participant questionnaire revealed only minor
side effects, of which a blocked nose, runny nose, and sneezing
were most often reported (Figure 6D). However, none of the par-
ticipants experienced one of these side effects for the entire
duration of the study, and several effects were reported only
once or twice over the entire study. In addition, these side effects
are often reported when using other nasal sprays as well (Ga-
nesh et al., 2017). Furthermore, C-reactive protein (CRP) levels
in the blood were normal in 15/20 of the volunteers, and only
slightly elevated in 5/20 participants (Table S7), which is in accor-
dance with our data on the low inflammatory reaction toward
L. casei AMBR2 in the Calu-3 cells (Figure 4B). This is in agree-
ment with the fact that the selected strain is adapted to and toler-
ated by the human nose, because no overt response upon
administration of the strain was observed. The few participants
Figure 6. In-Human Potential of URT Lactobacilli as Beneficial URT Taxa
(A) Schematic overview of the study setup with the different samples collected at the different time points. Volunteers administered the L. casei AMBR2 nasal
spray twice a day for 2 weeks. Time points were the start of the study (T0), 5min after first administration (T1), within 10–16 h after the last administration at the end
of the 14-day treatment (T2), and 2 weeks after the last administration (T3). A nasopharyngeal swab was collected at each time point, and a blood sample was
collected at the start of the study and after the 2 weeks of nasal administration.
(B) Quantitative estimation of the amount of L. casei AMBR2 in the nasopharynx after nasal administration at T0, T1, T2, and T3 determined via dedicated qPCR
targeting the srr2 gene of L. casei AMBR2. The detection limit was estimated to be at 103 CFUs. Significant differences are indicated with an asterisk (***p < 0.001,
****p < 0.0001).
(legend continued on next page)
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OPEN ACCESSin whom some mildly elevated CRP levels were found did not
report any signs of infection themselves, and one participant
already displayed elevated CRP levels prior to the start of the
study (Table S7). In addition, no signs of acute inflammation
were observed upon physical examination of the upper airways.
Furthermore, blood samples were cultivated on selective MRS
agar plates to investigate the presence of L. casei AMBR2 in
the blood. Samples from all participants were negative, indi-
cating that translocation to the blood was below detection limit
in these volunteers.
DISCUSSION
Lactobacilli have been described as important beneficial species
of the gastrointestinal tract (Heeney et al., 2018), the vagina (Pet-
rova et al., 2015), and the skin (Lebeer et al., 2018) of humans,
many animals, and fermented foods, because of their antimicro-
bial and/or immunomodulatory capacities. They have conse-
quently been investigated for their health-promoting properties
in several of these habitats. In contrast, although there exist
some occasional reports that detected lactobacilli in the URT
(Abreu et al., 2012; Bogaert et al., 2011; Jensen et al., 2013;
Ling et al., 2013; Stearns et al., 2015), their importance as com-
mensals in the URT and their ability to colonize and function in
this habitat have not been explored. In this study, we integrated
a dedicated comparative microbiome profiling of the taxa in
health and CRS disease, with the cultivation of URT-specific
strains from healthy individuals as potential probiotics for the
URT. Several LAB (Lactobacillaceae and Carnobacteriaceae)
were clearly more prevalent in healthy individuals. Multiple iso-
lates were cultivated from the most abundant taxa of lactobacilli,
putatively classified as L. rhamnosus, L. casei, L. sakei, and
L. plantarum species. Because these isolated lactobacilli could
originate from fermented foods or commercial probiotics via
the oronasopharynx, we carefully analyzed their genetic and
functional adaptation capacity to the URT. We rationalized that
oxidative-stress tolerance and adherent properties are impor-
tant features for lactobacilli in order to be able to adapt and func-
tion in this habitat. One of our isolates, L. casei AMBR2, showed
the presence of a functional heme- and manganese-dependent
catalase, as well as a SecA2/SecY2 gene cluster encoding two
putative glycosylated large-surface adhesin proteins. SEM anal-
ysis revealed the presence of fimbriae-like structures on the
L. casei AMBR2 surface. These fimbriae structuresmight explain
why AMBR2 adhered well to the respiratory epithelium, irrespec-
tive of health or disease status of the primary NECs. Adherence
is believed to be an important feature to promote beneficial ac-
tions by probiotics to exert their beneficial effects, as demon-
strated, for instance, for the model L. rhamnosus GG with its in-
testinal mucus-specific SpaCBA pili (Lebeer et al., 2012; Vargas
Garcı´a et al., 2015). An additional advantage of adherent strains,
in particular for nasal applications, lies in their higher colonization(C) Relative abundances focusing on the dominant URT genera determined at
sequencing.
(D) Reported side effects during the 14-day nasal treatment with L. casei AMB
blockage, nasal bleeding, and crust formation. The number of complaints per sid
See also Table S6.
10 Cell Reports 31, 107674, May 26, 2020capacity, because they would otherwise be rapidly eliminated by
nasal clearance (Pandya and Tiwari, 2006). We further substan-
tiated the multifactorial beneficial mode of action of L. casei
AMBR2 in the URT, by demonstrating its anti-pathogenic effects
through growth inhibition of URT pathobionts in vitro, and its ca-
pacity to reduce inflammatory responses of airway epithelial
cells in co-culture with pathobionts.
The capacity of L. casei AMBR2 to withstand nasal clearance
and at least temporary colonize the nose was then investigated
in an open-label exploratory study in healthy participants. We
could detect L. casei AMBR2 in 60%–95% of the nasopharynx
samples, with MiSeq or qPCR, respectively, of the 20 healthy vol-
unteers up to 10–16 h after the last administration of a 2-week
treatment, and still in 10% (qPCR) to 35% (MiSeq) of the samples
studied 2 weeks after the last dose. Byway of comparison, Strep-
tococcus salivarius 24SMB, which in another study was used in a
nasal spray for 3 days, colonized the nasopharynx in 55% of the
volunteers for up to 6 days after the last dose, without any adverse
effects (Santagati et al., 2015). However, in the latter study, colo-
nization of the appliedStreptococcus strain was promoted by giv-
ing the participants an antibiotic treatment before the start of the
study (Santagati et al., 2015). We did not adopt such an approach
in healthy volunteers because of the increasing reports on long-
term consequences and side effects of such antibiotic treatments
(Langdon et al., 2016). In another study, inwhich the effect of a sin-
gle dose of 13 honeybee LAB in a honey-based formulation was
investigated in healthy volunteers, none of the applied LAB were
detected in the nose 2 weeks posttreatment based on cultivation
(Ma˚rtensson et al., 2016). The same group investigated the effects
of these honeybee LAB upon nasal administration in the URT of
CRS patients without nasal polyps (CRSsNP) and demonstrated
that application of these lactobacilli for 2 weeks was safe, but
no beneficial effects on symptom severity nor the microbiota
were observed in the patients (Ma˚rtensson et al., 2017). This sug-
gests that lactobacilli originating from another environment might
have less potential for application in the human nose.
In conclusion, lactobacilli have been widely studied in the hu-
man gut and vagina, but knowledge on their role and beneficial
functions in the human URT is limited. A thorough analysis of
habitat-specific LGC species with a niche and adaptation poten-
tial to the URT environment had not been performed to date. Our
study showed that L. casei AMBR2, which was isolated from the
URT and shown to have superior properties in terms of oxidative-
stress tolerance and fimbriae structures, was able to adapt to
and colonize the human nasopharynx and was well tolerated.
This highlights the importance of Lactobacillus taxa in the URT
and the potential of L. casei AMBR2 as a probiotic for the URT.
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Bacterial and Virus Strains
Lactobacillus rhamnosus GG ATCC ATCC53103
Lactobacillus rhamnosus AMBR1 LAMB PRJEB32716
Lab of Applied Microbiology and
Biotechnology, University of
Antwerp, Belgium.
Lactobacillus casei AMBR2 LAMB BCCM/LMG P-30039 PRJEB21025
Lactobacillus rhamnosus AMBR3 LAMB PRJEB32716
Lactobacillus rhamnosus AMBR4 LAMB PRJEB32716
Lactobacillus rhamnosus AMBR5 LAMB PRJEB32716
Lactobacillus rhamnosus AMBR6 LAMB PRJEB32716
Lactobacillus rhamnosus AMBR7 LAMB PRJEB32716
Lactobacillus sakei AMBR8 LAMB PRJEB32716
Lactobacillus plantarum AMBR9 LAMB PRJEB32716
Haemophilus influenzae ATCC ATCC49247
Moraxella catarrhalis ATCC ATCC25238
Staphylococcus aureus ATCC ATCC29213
Biological Samples
adult human nasopharyngeal swabs University of Antwerp,
University Hospitals of Leuven
N/A
Chemicals, Peptides, and Recombinant Proteins
de Man, Rogosa and Sharpe (MRS) Difco BD288210
Mueller Hinton LabM limited LAB039-A
Hemin BioXtra, Sigma Aldrich 51280-1G
NAD VWR 53-84-9
Glucose Sigma Aldrich G8270-1KG
Minimal Essential Medium (MEM) Life Technologies 31095-029
Fetal Calf Serum (FCS) Hyclone 12350273
Penicillin-streptomycin (100U/mL) GIBCO 15140122
Trypsin EDTA (0.25%) GIBCO 25200072
Vancomycin CELLPURE 0242.3
Menaquinone Sigma Aldrich V9378-250MG
0.1% hexetidine (Hextril) Famar Orle´ans N/A
Pronase Sigma Aldrich 10165921001
DMEM-F12 GIBCO 11330032
Ultroser G Pall Life Sciences 15950-017
DynabeadsTM CD45 Thermofisher Scientific 11153D
DynabeadsTM CD15 Thermofisher Scientific 11137D
Lysozyme Sigma Aldrich L6876-5G
mutanolysin (100 U/mL) Sigma Aldrich M9901-10KU
PBS GIBCO 14040-091
Readyscript cDNA synthesis mix Sigma Aldrich RDRT-500RXN
PowerSYBR Green PCR Master Mix Applied Biosystems 13266519
Critical Commercial Assays
NucleoSpin 96 Tissue kit Machery-Nagel MN 740609.50
Nextera XT DNA Sample Preparation kit Illumina TG-131-1096
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QIAamp Powerfecal DNA kit QIAGEN 12830-50
Agencourt AMPure XP Beckman Coulter A63881
RNeasy Mini kit QIAGEN 74104
NuPAGE Novex 3-8% Tris-Acetate gels Invitrogen EA0375PK2
Deposited Data
Lactobacillus rhamnosus AMBR1 This paper PRJEB32716
Lactobacillus casei AMBR2 (Wuyts et al., 2017) PRJEB21025
Lactobacillus rhamnosus AMBR3 This paper PRJEB32716
Lactobacillus rhamnosus AMBR4 This paper PRJEB32716
Lactobacillus rhamnosus AMBR5 This paper PRJEB32716
Lactobacillus rhamnosus AMBR6 This paper PRJEB32716
Lactobacillus rhamnosus AMBR7 This paper PRJEB32716
Lactobacillus sakei AMBR8 This paper PRJEB32716
Lactobacillus plantarum AMBR9 This paper PRJEB32716
DNA-Seq data study B300201524257 (De Boeck et al., 2017, 2019) PRJEB23057, PRJEB30316
DNA-Seq data study B300201835709 This paper PRJEB32716
Experimental Models: Cell Lines
Calu-3 ATCC HTB-55
Primary Nasal Epithelial Cells University Hospitals Leuven N/A
Oligonucleotides
16S rRNA gene (27F) AGAGTTTGATCMTGGCTCAG (Lane, 1991) N/A
16S rRNA gene (1492R)GGTTACCTTGTTACGACTT (Turner et al., 1999) N/A
Srr2 (2759F) CCCGGGCCGTTACGTTGCAGGCAAAA This study N/A
Srr2 (2841R)ACTAGTTAATTGGTCAGTCGGTGCCC This study N/A
CYC1-F (qPCR)CATGTCCCAGATAGCCAAGGA (Moretti et al., 2019) N/A
CYC1-R (qPCR)CTTGTGCCGCTTTATGGTGTAG (Moretti et al., 2019) N/A
ATP5B-F (qPCR)GCAGGAAAGAATTA
CCACTACCAAG
(Moretti et al., 2019) N/A
ATP5B-R (qPCR)TGGTAGCATCCAAATGGGCAA (Moretti et al., 2019) N/A
IL1b-F (qPCR)TTGCTCAAGTGTCTGAAGCAGC (Moretti et al., 2019) N/A
IL1b-R (qPCR)CAAGTCATCCTCATTGCCACTG (Moretti et al., 2019) N/A
IL8-F (qPCR)TGGCAGCCTTCCTGATTTCT (Moretti et al., 2019) N/A
IL8-R (qPCR)TTAGCACTCCTTGGCAAAACTG (Moretti et al., 2019) N/A
TNF-F (qPCR)CCTCTGATGGCACCACCAG (Moretti et al., 2019) N/A
TNF-R (qPCR)TCTTCTCGAACCCCGAGTGA (Moretti et al., 2019) N/A
Software and Algorithms
GraphPad Prism GraphPad Software https://www.graphpad.com/
DADA2, version 1.6.0 https://doi.org/10.1038/
nmeth.3869
https://benjjneb.github.io/dada2/index.html
R version 3.4.4 (R Foundation for Statistical
Computing, 2018)
(R Core Team, 2018) https://www.r-project.org/
Tidyamplicons (SWittouck/tidyamplicons: Functions
to Manipulate and Visualize Amplicon
Abundance Data)
https://github.com/Swittouck/tidyamplicons
SPAdes 3.12.0 (Bankevich et al., 2012) http://cab.spbu.ru/software/spades/
checkM (Parks et al., 2015) https://ecogenomics.github.io/CheckM/
Prokka 1.12 (Seemann, 2014) https://github.com/tseemann/prokka
fastANI (Jain et al., 2018) https://github.com/ParBLiSS/FastANI
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Blastp (Altschul et al., 1990; Camacho
et al., 2009)
https://blast.ncbi.nlm.nih.gov/Blast.cgi?
PAGE=Proteins
snippy 4.3.6 N/A https://github.com/tseemann/snippy
OrthoFinder (Emms and Kelly, 2015) https://github.com/davidemms/OrthoFinder
Mafft (Katoh and Standley, 2013) https://mafft.cbrc.jp/alignment/software/
RAxML (Stamatakis, 2014) https://cme.h-its.org/exelixis/web/
software/raxml/
qbase+ (Vandesompele et al., 2002) https://www.qbaseplus.com/
Virulence Factor Database (VFDB) (Liu et al., 2019) http://www.mgc.ac.cn/VFs/
Other
MiSeq Desktop sequencer Illumina (M00984, Illumina)
Spray drier B-290, B€uchi B€uchi B-290, B€uchi
Synergy HTX multi-mode reader Biotek N/A
Leica EM CPD030 Leica Microsystems CPD030
Leica EM Ace 600 coater Leica Microsystems EM Ace600
Quanta Scanning Electron Microscopy ThermoFisher Scientific Quanta FEG250 SEM system
Take3 Biotek N/A
StepOne Plus Real-Time PCR System (v.2.0) Applied Biosystems N/A
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sarah
Lebeer (sarah.lebeer@uantwerpen.be).
Materials Availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
Data and Code Availability
All sequencing data were deposited in ENA (https://www.ebi.ac.uk/ena) under accession numbers PRJEB23057, PRJEB30316, and
PRJEB32716. All AMBR genomes were deposited under accession number PRJEB32716 and PRJEB21025 for L. casei AMBR2. The
R code generated during this study can be found on GitHub at https://github.com/Swittouck/urt_crs
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
For the microbiome comparison, human subjects, aged between 18 and 65 years, were recruited and sampled according to study
B300201524257 (ClinicalTrials.gov Identifier: NCT02933983). Nasopharyngeal samples were obtained from 100 healthy adult partic-
ipants (39%male, average age 34 years) and 225 adult CRS patients (63% male, average age 42 years). The informed consent was
obtained from all participants prior to sampling.
For the pilot study testing the fit-for-purpose L. casei AMBR2 nasal spray, 20 healthy adult male/female volunteers, aged between
18 and 65 years, were recruited and enrolled in the study (40% male, average age 36.7 years). Exclusion criteria were participants
taking corticosteroid medication and participants suffering from chronic airway diseases. This study was approved by the Ethics
Committee of the Antwerp University Hospital/University of Antwerp (registration number B300201835709, registered 5 March
2018, ClinicalTrials.gov Identifier: NCT03587545). The informed consent was obtained from all participants prior to sampling.
Microbe strains and culture
Microbial strains used are listed in the Key Resources Table. Lactobacillus strains were grown at 37C without agitation in de Man,
Rogosa and Sharpe (MRS) broth (Difco, Erembodegem, Belgium).Moraxella catarrhalis ATCC25238was inoculated inMueller Hinton
(MH) broth (LabM Limited) and cultured aerobically at 37C, Staphylococcus aureuswas grown at 37Cwithout agitation in MH broth
and Haemophilus influenzae ATCC49247 was grown at 37Cwith 5%CO2 in MH broth enriched with 0.5% of yeast extract, 15 mg/Le3 Cell Reports 31, 107674, May 26, 2020
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OPEN ACCESShemin and 15 mg/L NAD (Sigma Aldrich). Solid media contained 1.5% (v/w) agar. For antimicrobial assays, the media of the tested
pathogens was supplemented with glucose (5 g/L) (Sigma Aldrich).
Cell culture
The human bronchial epithelial cell line Calu-3 ATCC HTB-55TM (ATCC) was cultured at 37C with 5% CO2 and 90% relative hu-
midity in 75 cm2 cell tissue flasks containing 20 mL Minimal Essential Medium (MEM) (Life Technologies, Ghent, Belgium) supple-
mented with 10% heat inactivated fetal calf serum (FCS) (Hyclone) and penicillin-streptomycin (100 U/mL) (Life Technologies). Every
three or four days, the culture mediumwas changed and cells reaching 70%–80% confluency were reseeded at a 1:2 split ratio using
a 0.25% trypsin-EDTA solution (Life Technologies). Calu-3 cells were seeded in 12-well or 24-well culture plates (Cellstar, Diegem,
Belgium) for adhesion and immunomodulation experiments respectively, at a density of 3 3 105 cells/cm2 (1.1 3 106 cells/mL).
Approximately one week after seeding, confluent monolayers were obtained. One day before an experiment, medium was replaced
to MEM without any supplements.
Primary cell cultures
Inferior turbinates or polyps were used for isolation of nasal epithelial cells (NECs) at the University Hospitals of Leuven after patients
gave informed consent. The inferior turbinate was collected from non-allergic, non-smoking, non-asthmatic healthy controls during
aesthetic and/or functional rhinoplasty. Polyps were collected during FESS from non-allergic, non-smoking CRSwNP patients. A
highly purified NEC population was obtained, as reported previously (Bobic et al., 2010). Tissue was washed in sterile saline and
enzymatically digested in 0.1% Pronase (Protease XIV, Sigma) solution in DMEM-F12 culture medium supplemented with 100 U/
mL penicillin, 100 mg/mL streptomycin, and 2% Ultroser G (Pall Life Sciences, Zaventem, Belgium). After overnight incubation at
4C while shaking, the protease reaction was stopped by the addition of fetal calf serum (FCS) (10%). Cells were washed in culture
medium and pelleted by means of centrifugation for 5 min at 100 x g. Cells were then resuspended in 10 mL of culture medium and
incubated in a plastic culture flask for 1 h at 37C to remove fibroblasts. The cell suspensionwasmixedwith 23 107 prewashedCD45
and CD15 magnetic beads (Dynabeads; Invitrogen, Merelbeke, Belgium), and epithelial cells were purified by means of negative se-
lection, according to the manufacturer’s instructions. Cell purity was verified by using cytospin preparations and was found to be
98%or higher. Freshly isolated NECswere seeded in 12-well culture plates (Cellstar) at a density of 53 105 cells/mL. One day before
an experiment, medium was replaced to DMEM-F12 without any supplements.
METHOD DETAILS
Large-scale microbiome comparison: study design, sample collection and Illumina MiSeq 16S rRNA amplicon
sequencing
For microbiome comparison, nasopharyngeal samples were processed and sequenced as previously described (De Boeck et al.,
2017, 2019). Briefly, dual-index paired-end sequencingwas performed on the V4 region of the 16S rRNA gene using aMiSeqDesktop
sequencer (M00984, Illumina). Processing and quality control of the reads were performed for each run separately using the R pack-
age DADA2, version 1.6.0. Briefly, this entailed quality filtering of the reads, dereplication, denoising, removal of chimeras and read
classification. All data handling and visualization was performed in R version 3.4.4 (R Core Team, 2018) using the tidyverse set of
packages and the in-house package tidyamplicons (https://github.com/Swittouck/tidyamplicons).
The compositional analysis of differential abundance between CRS and control samples was inspired by the ANCOM method
(Mandal et al., 2015). Read counts were first aggregated on the family level (the families Lactobacillaceae and Leuconostocaceae
were merged into a single family representing the LGC). For each combination of a family and a reference family, the logratio of their
relative abundances was calculated per sample and a Wilcoxon rank-sum test was executed to assess differential abundance be-
tween the healthy controls and CRS patients. Significant differences were then determined from the Wilcoxon p values by capping
the false discovery rate at 10% with the method of Benjamini and Yekutieli (2001). To quantify the differential abundances, we used
the two-sample Hodges–Lehmann estimator (the median of all pairwise differences between the samples). The R code of these an-
alyses can be found on GitHub at https://github.com/Swittouck/urt_crs.
Intervention study with L. casei AMBR2 nasal spray
The L. caseiAMBR2was spray dried in a co-current systemwith a two-fluid nozzle (orifice diameter 1.4mm) under aseptic conditions,
without addition of excipients, at an initial inlet temperature of 135C, feed (bacterial suspension) flow rate of 7.5 mL/min, air flow rate
of approx. 32.5 m3/h, spray flow rate of 831 L/h and constant outlet temperature of 55C. Briefly, bacterial cells were grown to the
stationary phase, harvested, and dried using a laboratory-scale air spray dryer (B-290, B€uchi, Flawil, Switzerland) (Broeckx et al.,
2017). Spray-dried powder was collected from a single cyclone separator continuously throughout the process. Quality of the prod-
uct was investigated via the total microbial aerobic count (TAMC), total combined yeasts/molds count (TYMC) according to the Eu-
ropean Pharmacopoeia (PH. Eur. 2.6.12) (no more than 102 CFU/g), and by evaluating S. aureus and Pseudomonas aeruginosa
absence (absent in 1 g). Nasal spray formulations were prepared by adding 30 mg of spray-dried L. casei AMBR2 powder containing
1011 CFU/g of live bacteria at the moment of production in a specific glass bottle with nasal spray applicator (Pharma Pack, Wilrijk,
Belgium) in aseptic conditions. During the two weeks of the study, participants had to resuspend the powder in a 3 mL flush syringeCell Reports 31, 107674, May 26, 2020 e4
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was required. The packed product was stored at 4C and the stability of the product was tested after 2, 4, and 6 weeks to ensure
that the final concentration of administered bacteria was at least 108 CFU per puff. All participants administered the spray twice a
day for 14 days, by one puff in each nostril. Participants were followed up for an entire month with three visits to the ENT outpatients’
clinic. Nasopharyngeal samples of the study participants were collected by the responsible ENT specialist at the start of the study,
5 min after the first administration, after two weeks of spraying (within 10-16 h after the last administration), and finally after an addi-
tional two weeks without intervention. To detect the presence of L. casei AMBR2 in the nasopharyngeal samples, qPCRwith specific
primers for the srr2 gene of AMBR2 was performed (Key Resources Table). Blood samples for assessing inflammatory markers and
complete blood count analysis were collected at the start of the study and after twoweeks. Participants had to fill in a questionnaire to
report side effects, including sneezing, runny nose, blocked nose, and bleeding nose. Dual-index paired-end sequencing of the naso-
pharyngeal samples was performed on the V4 region of the 16S rRNA gene on a MiSeq Desktop sequencer (M00984, Illumina), as
described above.
Isolation and whole genome sequencing of Lactobacillus isolates from the healthy URT
Nasopharyngeal swabs from healthy volunteers were cultivated in MRS broth with 20 mg/mL vancomycin to promote the
growth of Lactobacillus species. Of note, special culture conditions relevant to the URT, such as decreasing the growth tem-
perature to 34C (in vivo nasopharynx temperature), and addition of menaquinone (1 mg/mL) and hemin (2.5 mg/mL) did not in-
crease the isolation frequency. Grown cultures were plated on MRS agar and single colonies were further identified with PCR
and Sanger sequencing of the 16S rRNA gene (27F-1492R). Lactobacillus-positive colonies were stored at 80C in 25% v/v
glycerol. Total DNA was extracted for whole genome sequencing using the NucleoSpin 96 Tissue kit (Machery-Nagel, D€uren,
Germany) with additional lysis step using 20 mg/mL lysozyme (Sigma-Aldrich, St. Louis, MO, USA) and 100 U/mL mutanolysin
(Sigma Aldrich). Whole genome sequencing was performed with the Nextera XT DNA Sample Preparation kit (Illumina, San
Diego, CA), followed by sequencing with the Illumina MiSeq platform (2 3 300 cycles) at the Center of Medical Genetics Ant-
werp (University of Antwerp).
Genome analysis
To improve phylogenetic analysis of the isolated AMBR genomes, all genomes that were used in the study of Sun et al. were retrieved
from the National Center for Biotechnology Information (NCBI) Assembly database and included in this study as reference strains
(Sun et al., 2015). Assembly was performedwith SPAdes 3.12.0 (Bankevich et al., 2012). The completeness of the genomeswas eval-
uatedwith checkM (Parks et al., 2015) and all genomeswith a completeness lower than 95%were discarded. Prokka 1.12 (Seemann,
2014) was used to predict and annotate genes for all genome sequences. A phylogenetic tree was built using single-copy core or-
thogroups as described in Wuyts et al., 2019). Furthermore, ANI was calculated using fastANI (Jain et al., 2018). The presence of
catalase and superoxide dismutase (SOD) genes was screened for using the same approach as described in Wuyts et al. (2017).
SpaCBA and srr2 genes presence was assessed with a BLAST search at protein level using blastp (Altschul et al., 1990; Camacho
et al., 2009) with the protein sequences of the genes of interest as query and the protein sequences encoded by the genomes as
reference. Finally, variant calling was performed using snippy 4.3.6. All genomes were uploaded under accession number
PRJEB32716 and PRJEB21025 for L. casei AMBR2 .
For the presence/absence assessment of heme- andmanganese-dependent catalase genes across the Lactobacillus genus com-
plex (LGC), the gene families of the in-house ‘‘lactobacillus evolutionary genomics’’ (legen) pipeline, version 2, were used. Briefly, in
this pipeline, the pangenome of the LGC was determined in three major steps. First, genomes were prepared: all publicly available
LGC genomes were downloaded from GenBank, they were filtered based on estimated completeness and contamination and their
core genes were extracted. Second, a de novo species-level taxonomy was constructed for these genomes by clustering them
based on pairwise genome core nucleotide identities. De novo species were named based on comparisons to published species
(Wittouck et al., 2019). Only species were retained with five or more genomes available and for species with more than 50 genomes,
the 50 highest quality genomes were selected. Finally, the pangenome of the remaining genomes was determined in the following,
hierarchical way. The pangenome of each of the species was inferred separately using the pangenome tool OrthoFinder (Emms and
Kelly, 2015). Next, these species-level pangenomes were collapsed by only selecting a single representative sequence for each spe-
cies-level gene family. Then, the collapsed species-level pangenomes were subjected to another round of gene family inference, also
using OrthoFinder. Inflating the resulting LGC-level gene families with the species-level families again then yielded the pangenome of
the entire LGC. To identify the gene families corresponding to the heme- and manganese-dependent catalases, a profile HMM data-
base was constructed for the gene families. The sequence of an experimentally confirmed heme-dependent catalase as well as that
of a manganese-dependent catalase (Table S8) were then searched against this database and the best-scoring profile (gene family)
was selected for each one.
To infer a phylogeny of LGC species, a supermatrix was first constructed from nucleotide sequences of single-copy core genes,
using mafft (Katoh and Standley, 2013). The tree was then inferred with RAxML (Stamatakis, 2014), with the General Time Reversible
(GTR) model and the ‘‘-f a’’ option, which performs rapid bootstrapping first and then goes through multiple stages of optimizing the
highest- likelihood trees of the previous stage, to ultimately end up with a single best tree.e5 Cell Reports 31, 107674, May 26, 2020
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The antimicrobial activity of isolated lactobacilli and L. rhamnosus GG against S. aureus, M. catarrhalis, and H. influenzae was
explored by standard antimicrobial tests, as described in van den Broek et al. (2018). Briefly, 2 mL of each Lactobacillus culture
was spotted on a standard agar plate (1.5% w/v) containing medium of the pathogen supplemented with glucose (5 g/L). These
plates were incubated for 48 h at 37C. After incubation, 450 mL, 45 mL and 300 mL of an overnight culture of M. catarrhalis,
S. aureus andH. influenza, respectively, were inoculated in soft agar (0.5%w/v) and poured over the plates with Lactobacillus spots.
The plates were incubated overnight according to the appropriate growth conditions of the tested pathogens, after which time the
inhibition zones were measured. 0.1% hexetidine (Hextril, Famar Orle´ans, Orle´ans, France) was used as a positive control while a
spot of the pathogenic bacterium itself served as a negative control.
Minimal inhibitory concentration (MIC) assay with isolated Lactobacillus species
The MIC values of several antimicrobials, as listed by EFSA (EFSA Panel on Biological Hazards (BIOHAZ), 2013), were determined
based on an earlier described procedure (Nizet et al., 2001). Lactobacilli were grown in MRS medium as described above. A 96-well
plate was filled to obtain a total volume of 100 mL at a final concentration of 5 3 105 CFU/mL of the lactobacilli combined with an
adequate concentration of the activemolecule. Themicroplate was incubated overnight at 37Cand theOD at 600 nmwasmeasured
using a Synergy HTX multi-mode reader (Biotek, Drogenbos, Belgium).
Scanning electron microscopy
Scanning electron microscopy (SEM) was used to visualize the presence or absence of pili or fimbriae on the bacterial surfaces,
as described in Wuyts et al., 2019). Briefly, grown bacteria were spotted on a gold-coated membrane (approximately 107 CFU
per membrane) and fixed with 2.5% (m/v) glutaraldehyde in 0.1 M sodium cacodylate buffer (2.5% glutaraldehyde, 0.1 M so-
dium cacodylate, 0.05% CaCl2.2H2O at pH 7.4) by gentle shaking for 1 h at room temperature (RT), followed by a further over-
night fixation at 4C. Bacteria were then rinsed 3x20 min and left overnight in cacodylate buffer (containing 7.5% (m/v) saccha-
rose). Subsequently, bacteria were dehydrated in a series of ethanol solutions in ascending concentrations and critical point
dried in a Leica EM CPD030 (Leica Microsystems Belgium, Diegem, Belgium). The membranes were mounted on a stub and
coated with 5 nm of carbon in a Leica EM Ace 600 coater (Leica Microsystems Belgium). SEM imaging was performed with
a Quanta FEG250 SEM system (Thermo Fisher, Asse, Belgium) at the Electron Microscopy for Material Science group
(EMAT, University of Antwerp).
Adherence assays to human airway Calu-3 epithelial cells and primary nasal epithelial cells
Experiments to assess the adhesion of bacterial strains to Calu-3 cells were carried out according to the methods described in Leb-
eer et al. (Lebeer et al., 2012). OnemL of the bacterial suspensions at a concentration of 13 108 CFU/mL was added to tissue culture
plates containing Calu-3 cells or primary NECs. Bacteria were incubated with the human cells for one h at 37C to allow adherence.
After incubation, cells were rinsed oncewith prewarmed PBS. To detach the cells, 300 mL of trypsin (0.25%)was added to the cells for
10min at 37C.When the cells had been detached, 700 mL PBSwas added and serial dilutions were plated out on solidMRSmedium
for Lactobacillus. The percentage of bacterial adhesion was calculated by comparing the total number of colonies counted after
adhesion with the number of cells in the bacterial suspension originally added to the cells.
Induction of cytokine gene expression in human airway Calu-3 epithelial cells at mRNA level
OnemLof the bacterial suspensions at a concentration of 13 108 CFU/mLwas added to tissue culture plates containing Calu-3 cells.
Bacteria were incubated for four hours at 37C with 5% CO2 and 90% relative humidity to induce cytokine gene expression. After
incubation, cells were rinsed three times with prewarmed PBS. MEM was used as negative control. RNA was extracted with the
RNeasy Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol and stored at 80C. One mg of isolated
RNA, quantified with Take3 (Biotek), was used for cDNA synthesis using Readyscript cDNA synthesis mix (Sigma Aldrich). After
geNorm analysis in qbase+ (Vandesompele et al., 2002), cytochrome c-1 (CYC1) and ATP synthase subunit beta (ATP5B) were
selected as reference genes. The expression of these reference genes with the expression of IL-8, IL-1b, and TNF was quantified
by RT-qPCR on a StepOne Plus Real-Time PCR System (v.2.0; Applied Biosystems, Foster City, California, United States). Primers
were tested for their efficiencies between 90%–110%. All primers were designed on the basis of published sequences (Moretti et al.,
2019) and chemically synthesized by Integrated DNA Technologies (IDT, Leuven, Belgium) (Key Resources Table). Each cDNA sam-
ple was amplified in duplicate with PowerSYBRGreen PCRMasterMix (Applied Biosystems) in a total volume of 20 mLwith 0.15 mM
of each primer, 40 ng of cDNA and nuclease-free water. Data are presented as the ratio of the amount of cytokine mRNA to the
amount of reference mRNA. Non-template controls were included for each run.
Surface proteome extraction
To extract the surface proteins from L. caseiAMBR2, an overnight culture (300mL) was pelleted andwashedwith PBS. The cell pellet
was dissolved in PBS (30mL) and the surface proteins were loosened by subsequent sonication (20min; 20’ on, 20’ off, 20%), freezing
and thawing. This cycle was repeated twice. Afterward, the cells were removed by cycles of centrifugation at increasing speed (4000
x g, 4500 x g, 4750 x g, each 15 min, 4C). The protein fraction in the supernatant was precipitated by overnight incubation in twoCell Reports 31, 107674, May 26, 2020 e6
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Tris-Acetate gels (Life Technologies).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments can be found in the figure legends, including the statistical tests used, exact value of n, the definition
of center, and dispersion and precision measures. For adherence assays and qPCR data, one-way ANOVA and multiple t tests were
used to determine statistical significance in GraphPad Prism. The p value was corrected for multiple comparisons using the Holm-
Sidak method in GraphPad Prism. For the prevalence and abundance of lactobacilli in the URT of healthy controls and CRS patients
(Figure 1), Wilcoxon rank-sum test was executed to assess differential abundance between the healthy controls and CRS patients.
Significant differences were then determined from theWilcoxon p values by capping the false discovery rate at 10%with the method
of Benjamini and Yekutieli (Benjamini and Yekutieli, 2001). p values for comparison of prevalence and mean relative abundance be-
tween heathy controls and CRS patients were determined with a Fischer’s exact test and Wilcoxon rank-sum test, respectively.e7 Cell Reports 31, 107674, May 26, 2020
